Literature DB >> 19786624

Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Jeannette Zinggeler Berg1, Jesse Mason, Angela J Boettcher, Dorothy K Hatsukami, Sharon E Murphy.   

Abstract

Nicotine is the major addictive agent in tobacco smoke, and it is metabolized extensively by oxidation and glucuronide conjugation. The contributions of ethnicity and UGT2B10 haplotype on variation in nicotine metabolism were investigated. Nicotine metabolism was evaluated in two populations of smokers. In one population of African American and European American smokers (n = 93), nicotine and its metabolites were analyzed in plasma and 24-h urine over 3 days while participants were abstinent and at steady state on the nicotine patch. In a second study of smokers (n = 84), the relationship of a UGT2B10 haplotype linked with D67Y to nicotine and cotinine glucuronidation levels was determined. We observed that both African American ethnicity and the UGT2B10 D67Y allele were associated with a low glucuronidation phenotype. African Americans excreted less nicotine and cotinine as their glucuronide conjugates compared with European Americans; percentage of nicotine glucuronidation, 18.1 versus 29.3 (p < 0.002) and percentage of cotinine glucuronidation, 41.4 versus 61.7 (p < 0.0001). In smokers with a UGT2B10 Tyr67 allele, glucuronide conjugation of nicotine and cotinine was decreased by 20% compared with smokers without this allele. Two key outcomes are reported here. First, the observation that African Americans have lower nicotine and cotinine glucuronidation was confirmed in a population of abstinent smokers on the nicotine patch. Second, we provide the first convincing evidence that UGT2B10 is a key catalyst of these glucuronidation pathways in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786624      PMCID: PMC2802474          DOI: 10.1124/jpet.109.159855

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

Authors:  Kerri A Schoedel; Ewa B Hoffmann; Yushu Rao; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenetics       Date:  2004-09

2.  A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers.

Authors:  Sharon E Murphy; Carrie A Link; Joni Jensen; Chap Le; Susan S Puumala; Stephen S Hecht; Steven G Carmella; London Losey; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-10       Impact factor: 4.254

3.  Effects of watercress consumption on urinary metabolites of nicotine in smokers.

Authors:  S S Hecht; S G Carmella; S E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

4.  Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study.

Authors:  L E Wagenknecht; G R Cutter; N J Haley; S Sidney; T A Manolio; G H Hughes; D R Jacobs
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

5.  Ethnic differences in N-glucuronidation of nicotine and cotinine.

Authors:  N L Benowitz; E J Perez-Stable; I Fong; G Modin; B Herrera; P Jacob
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

6.  Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.

Authors:  M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

7.  Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

Authors:  Ursula Ehmer; Arndt Vogel; Jan Karl Schütte; Britta Krone; Michael P Manns; Christian P Strassburg
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

8.  Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.

Authors:  Sanna Kaivosaari; Päivi Toivonen; Olli Aitio; Julius Sipilä; Mikko Koskinen; Jarmo S Salonen; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-05-12       Impact factor: 3.922

9.  Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer.

Authors:  Kiersten S Derby; Kristine Cuthrell; Christian Caberto; Steven G Carmella; Adrian A Franke; Stephen S Hecht; Sharon E Murphy; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11-24       Impact factor: 4.254

10.  Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.

Authors:  Gary E Swan; Christina N Lessov-Schlaggar; Andrew W Bergen; Yungang He; Rachel F Tyndale; Neal L Benowitz
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

View more
  34 in total

1.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Authors:  Sharon E Murphy; Christopher J Sipe; Kwangsoo Choi; Leah M Raddatz; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-06       Impact factor: 4.254

3.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

4.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

5.  The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.

Authors:  Rachel I Vogel; Steven G Carmella; Irina Stepanov; Dorothy K Hatsukami; Stephen S Hecht
Journal:  Biomarkers       Date:  2011-08-03       Impact factor: 2.658

6.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

7.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

8.  Prenatal tobacco exposure and cotinine in newborn dried blood spots.

Authors:  Logan G Spector; Sharon E Murphy; Katherine M Wickham; Bruce Lindgren; Anne M Joseph
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

9.  Intraindividual covariation between e-cigarette and combustible cigarette use in Korean American emerging adults.

Authors:  Jimi Huh; Adam M Leventhal
Journal:  Psychol Addict Behav       Date:  2015-11-30

10.  Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes.

Authors:  Gideon St Helen; Peyton Jacob; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2013-05-14       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.